Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C61087
http://purl.obolibrary.org/obo/NCIT_C61087
|
|---|---|
| Preferred Name | Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine |
| Definitions |
A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) types 6, 11, 16, and 18 with immunoprophylactic activity. L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae, self-assembled into VLPs, and adsorbed onto amorphous aluminium hydroxyphosphate sulfate adjuvant following purification. The immunoprophylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A non-infectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid (L1) protein of human papillomavirus (HPV) types 6, 11, 16, and 18 with immunoprophylactic activity. L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae, self-assembled into VLPs, and adsorbed onto amorphous aluminium hydroxyphosphate sulfate adjuvant following purification. The immunoprophylactic efficacy of L1 VLP vaccines, such as quadrivalent human papillomavirus (types 6,11,16,18) recombinant vaccine, appear to be mediated by the development of humoral immune responses. HPV Types 16 and 18 account for approximately 70% of cervical cancers and HPV Types 6 and 11 account for approximately 90% of genital warts. |
|---|---|
| prefLabel | Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine
|
| label | Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine
|
| PDQ_Closed_Trial_Search_ID | 476576
|
| code | C61087
|
| prefixIRI | NCIT:C61087
|
| in_subset |
See more
See less
|
| Display_Name | Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine
|
| Preferred_Name | Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine
|
| Contributing_Source | CTRP
|
| Maps_To | Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine
|
| NCI_Drug_Dictionary_ID | 476576
|
| Legacy Concept Name | Quadrivalent_Human_Papillomavirus_Recombinant_Vaccine
|
| type | |
| ALT_DEFINITION | A vaccine used to prevent cervical, vulvar, and vaginal cancer caused by human papillomavirus (HPV) types 16 and 18 and genital warts caused by HPV types 6 and 11. It is also used to prevent lesions that are caused by these viruses and that can lead to cervical, vulvar, or vaginal cancer. Quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine is used in females aged 9-26 years. It is also used to prevent genital warts in males aged 9-26 years. Quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine is being studied in the treatment of other medical conditions.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 476576
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C1831799
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |